Why oncology marketers must think beyond the brand
“The product hasn’t changed. But the market it was built for has.”Barry Vucsko, SVP, Strategic Development, EVERSANA INTOUCH
In oncology, a brand’s biggest threat may not be a direct competitor. It may be a treatment decision made months or even years earlier.
As antibody-drug conjugates (ADCs), bispecific antibodies, CAR-T therapies, and new diagnostics move into earlier lines of treatment, the patients reaching any given brand are changing, and so is the commercial opportunity.
In this point of view, Barry Vucsko, SVP, Strategic Development, EVERSANA INTOUCH, introduces the Sequencing Strategist: a commercial capability that connects medical affairs, competitive intelligence, market research, forecasting, and brand planning to anticipate how the entire treatment journey shapes where a brand fits today and tomorrow.
What You’ll Learn
- Why brand-centric planning can miss upstream shifts that reshape patient populations, forecasts, and positioning
- How a Sequencing Strategist thinks differently from a traditional brand manager
- What sequencing looks like in practice across ADCs in breast cancer, BCMA- and GPRC5D-targeted therapies in multiple myeloma, and ctDNA and MRD diagnostics
- Five questions to assess your organization’s sequencing readiness
Author
Barry Vucsko has more than 25 years of marketing, advertising, and consulting experience spanning more than 100 brands and several continents...